• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Prime Therapeutic Removes Several Products from its Medicare Formulary


Three products, including Pfizer’s smoking cessation product Chantix, have been removed because generics are now available.

Prime Therapeutics has made several changes to it Medicare Part D formulary, removing three products that now have generics available. Two products — Bystolic and Chantix — were removed effective Sept. 30, 2021.

Bystolic (nebivolol) is a beta blocker used to treat high blood pressure manufactured by Allergan, now a part of AbbVie, which acquired Allergan in May 2020. In September, Camber Pharmaceuticals launched a generic version of therapeutic. The generic version is available in several strengths, including 2.5 mg, 5 mg, 10 mg, and 20, mg.

A generic of Pfizer’s smoking cessation product Chantix (varenicline) was approved Aug. 11, 2021. Developed by Par Pharmaceutical, which is part of Endo International, the generic varenicline tablet was approved August 11, 2021. The generic will come in doses of 0.5 mg and 1 mg.

Related: FDA Approves Generic of Chantix, Pfizer's Smoking Cessation Drug

Related: Pfizer Recalls All Lots of Smoking Cessation Drug Chantix

The plans effected by these changes include Ideal Formularies, Value+ & client specific formularies, such as Alignment, Asuris, Capital Blue Cross, Health Care Service Corp, and Horizon.

Additionally, Prime Therapeutics has removed Durezol (difluprednate) from the Horizon Medicare Part D formulary effective Oct. 6, 2021. Durezol is manufactured by Novartis to treat and is used to treat inflammation and pain associated with ocular surgery. The FDA approved Cipla’s generic version of Durezol in August 2021.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.